China Nuokang Bio-Pharmaceutical Inc. Announces Date of Annual General Meeting

Published on Tuesday, 22 November 2011 09:13 Written by TradersHuddle Staff

BEIJING, Nov. 22, 2011 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that its annual general meeting will be held at 9 a.m. Beijing Time on December 23, 2011 at the Company's headquarter located at No. 18-1 East Nanping Road, Hunnan National New & High-tech Development Zone, Shenyang, Liaoning Province, P.R. China.

The primary agenda of the meeting is to appoint Ernst & Young Hua Ming as independent auditor of the Company for the fiscal year ending December 31, 2011.

Shareholders of record at the close of business on November 23, 2011 will be entitled to receive notice and to vote at the annual general meeting and any adjournment. Holders of the Company's American Depository Shares who wish to exercise their voting rights for the underlying shares must act through the depository. Shareholders are cordially invited to attend the annual general meeting.

A notice of the annual general meeting describing the matters to be considered at the meeting is available online at http://ir.nkbp.com/. The Company's annual report for the year ended December 31, 2010 is also available online.

Shareholders may receive a meeting notice, proxy statement and hard copy of 20-F free of charge upon request. Please send e-mail request to This e-mail address is being protected from spambots. You need JavaScript enabled to view it. and provide your complete mailing and contact details.

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 3,000 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information.

CONTACT: ICR, Inc.
         In the U.S.: Ashley De Simone: 1-646-277-1227
         In China: Wen Lei Zheng: 86-10-6583-7510